As of May 23, 2025, Lyell Immunopharma Inc (LYEL) reports a Net Margin of -562285.25%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Lyell Immunopharma Inc's Net Margin
Over recent years, Lyell Immunopharma Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -562285.25% |
| 2023-12-31 | -180486.16% |
| 2022-12-31 | -216.25% |
| 2021-12-31 | -2349.48% |
| 2020-12-31 | -2634.92% |
This slight upward trend highlights how Lyell Immunopharma Inc manages its overall profitability and cost control over time.
Comparing Lyell Immunopharma Inc's Net Margin to Peers
To better understand Lyell Immunopharma Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Lyell Immunopharma Inc (LYEL) | -562285.25% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Biogen Inc (BIIB) | 16.87% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, Lyell Immunopharma Inc's Net Margin is lower than all peers, which may indicate challenges in controlling expenses or competitive pricing pressures.